Evidence map›Paper›PMID 41388541›Full record

ArticleJournal of nanobiotechnology2025

Dual-targeted bacterial outer membrane vesicles enhance glioblastoma immunotherapy by regulating tumor microenvironment and inducing IFN-γ-mediated ferroptosis.

Chen Chen, Xiaojing Zhu, Zefeng Song, Yutong Xing, Wenrui Jin, Fan Li, Pir Tariq Shah, Siqi Song, Haoran Geng, Kai Xu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chen Chen *Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Xiaojing Zhu *Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Zefeng Song *Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Yutong XingShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Wenrui JinShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Fan LiShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Pir Tariq ShahFaculty of Medicine, Dalian University of Technology, Dalian, 116024, China.
Siqi SongShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Haoran GengShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China.
Kai XuDepartment of Spine Surgery, Central Hospital of Dalian University of Technology, Dalian, 116089, China.
Hong WangFaculty of Medicine, Dalian University of Technology, Dalian, 116024, China.
Zhenyong WuShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264117, Shandong, China. wuzhenyong@simm.ac.cn.

Funding

China Postdoctoral Science Foundation 2024M763416Dalian Key Medical Specialty Dengfeng Project 2022ZZ210Key R&D Program of Shandong Province 2024CXPT029Liaoning Province Clinical Key Specialty Project 2024SZ023National Natural Science Foundation of China 32371283Natural Science Foundation of Shandong Province ZR2024QB342Postdoctoral Fellowship Program of CPSF GZC20241828Shandong Laboratory Program SYS202205Special Supporting Funds for Leading Talents at or Above the Provincial Level in Yantai City 2023000090Taishan Scholars Program 2023000027
6 · The paper itself

Abstract

Glioblastoma (GBM) immunotherapy is limited by the blood-brain barrier (BBB) and the tumor immune resistance. Here, we develop an engineered bacterial outer membrane vesicle (OMV) through safe and straightforward genetic modification of Escherichia coli, termed OMV-C-C, enabling co-expression of cell-penetrating peptides (CPP) and chlorotoxin (CLT) on its surface. The OMV-C-C efficiently crosses BBB and specifically targets tumor cells both in vitro and in vivo. A single intravenous administration of OMV-C-C significantly inhibit GBM growth by enhancing the infiltration of CD8

Indexed as

Bacterial Outer MembraneBrain NeoplasmsFerroptosisGlioblastomaImmunotherapyInterferon-gammaTumor MicroenvironmentAnimalsBlood-Brain BarrierCell Line, TumorCell-Penetrating PeptidesEscherichia coliHumansMiceMice, NudeCell-Penetrating PeptidesInterferon-gamma

Identifiers

PMID41388541
PMCPMC12817401

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.